Mga Batayang Estadistika
| LEI | 529900ULKWCLO3ZHXL41 |
| CIK | 1137883 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Brainstorm Cell Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| August 14, 2025 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today anno |
|
| July 22, 2025 |
July 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-3 File No. 333-288322 Ladies and Gentlemen: On June 25, 2025, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), filed a Registration Statement on Form S-3 (File No. 3 |
|
| July 17, 2025 |
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB Exhibit 99.1 BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB NEW YORK, NY, July 17, 2025 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm's common stock on |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| July 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Brainstorm Cell Therapeutics Inc. |
|
| June 25, 2025 |
Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan. Exhibit 10.12 BRAINSTORM CELL THERAPEUTICS INC. AMENDMENT NO. 5 TO 2014 GLOBAL SHARE OPTION PLAN The 2014 Global Share Option Plan (the “Plan”) of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), is hereby amended by this AMENDMENT NO. 5 as follows: Section 5.1 of the Plan is hereby deleted in its entirety and a new Section 5.1 is inserted in lieu thereof which shall read |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Brainstorm Cell Therapeutics Inc. |
|
| June 25, 2025 |
Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. Exhibit 10.6 BRAINSTORM CELL THERAPEUTICS INC. AMENDMENT NO. 5 TO 2014 STOCK INCENTIVE PLAN The 2014 Stock Incentive Plan (the “Plan”) of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), is hereby amended by this AMENDMENT NO. 5 as follows: Section 4(a)(1) of the Plan is hereby deleted in its entirety and a new Section 4(a)(1) is inserted in lieu thereof which shall read |
|
| June 25, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 16, 2025 |
Exhibit 99.1 BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® NEW YORK, NY, June 16, 2025 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Progra |
|
| May 19, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 19, 2025 |
Exhibit 99.1 BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| May 15, 2025 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financia |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 21, 2025 |
Amendment No. 2 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025. Exhibit 3.1 BRAINSTORM CELL THERAPEUTICS INC. AMENDMENT NO. 2 TO THE BYLAWS OF BRAINSTORM CELL THERAPEUTICS INC. This Amendment No. 2 to the Bylaws, as amended by the Amendment No. 1 dated as of March 21, 2007 (as amended, the “Bylaws”) of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Corporation”), is effective as of April 20, 2025. ARTICLE I, SECTION 6 of the Bylaws entitled “Q |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 31, 2025 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Brainstorm Cell Manufacturing LLC Delaware Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. |
|
| March 31, 2025 |
Policy on Trading of Securities and Public Disclosures Exhibit 19.1 BRAINSTORM CELL THERAPEUTICS INC. POLICY ON TRADING OF SECURITIES AND PUBLIC DISCLOSURES Brainstorm Cell Therapeutics Inc. (“Brainstorm”) is a publicly traded company, hence, there are numerous obligations and restrictions imposed on Brainstorm, its subsidiaries and its Board of Directors and all employees of Brainstorm and its subsidiaries (collectively, “Brainstorm personnel”) by fe |
|
| March 31, 2025 |
Exhibit 10.83 June 27, 2023 Ibrahim (Bob) Dagher Re: Employment Offer Dear Mr. Dagher: I am pleased to offer you employment with BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”). The initial terms of your employment, should you accept this offer, are set forth below (the “Agreement”). 1.Position. Your position will be Chief Development Officer. You will have such duties as |
|
| March 31, 2025 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal ye |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 31, 2025 |
Exhibit 10.1 BRAINSTORM CELL THERAPEUTICS INC. March 31, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Brainstorm Cell Therapeutics Inc. (the “Company”) is pleased to offer to you (“Holder”, “you”, or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common sto |
|
| March 31, 2025 |
Form of Financial Advisory Agreement Exhibit 1.1 March 31, 2025 VIA ELECTRONIC DELIVERY Chaim Lebovits Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Dear Mr. Lebovits: We are pleased that Brainstorm Cell Therapeutics Inc. (collectively, with its subsidiaries the “Company”) has decided to retain Maxim Group LLC (the “Financial Advisor”) to provide general financial adv |
|
| March 31, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 31, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPE |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| January 21, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 14, 2024 |
BCLI / Brainstorm Cell Therapeutics Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-bcli093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value (Title of Class of Securities) 10501E300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| November 14, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK, November 14, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced finan |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 13, 2024 |
BCLI / Brainstorm Cell Therapeutics Inc. / Ruck Matthew J - 13G INITIAL Passive Investment SC 13G 1 mruckBCLI1112.htm 13G INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Initial Filing)* Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 10501E300 (CUSIP Number) November 13, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| October 30, 2024 |
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement NEW YORK, Oct. 30, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company ha |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| October 1, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BRAINSTORM CELL THERAPEUTICS INC. a Delaware corporation Brainstorm Cell Therapeutics Inc. (hereinafter called the “Corporation”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: The Board of Directors of the Corporation, at a duly called a |
|
| October 1, 2024 |
Exhibit 99.1 Brainstorm Cell Therapeutics Nasdaq: BCLI 2 Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause Brainstorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrase |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation |
|
| October 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| September 26, 2024 |
Brainstorm Cell Therapeutics, Inc. 1325 Avenue of Americas, 28th Floor New York, New York 10019 (201) 488-0460 September 26, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Brainstorm Cell Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-282172) (the “Registration Stat |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation |
|
| September 24, 2024 |
Brainstorm Cell Therapeutics, Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Brainstorm Cell Therapeutics, Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 September 24, 2024 Via EDGAR Submission U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford and Laura Crotty Re: Brainstorm Cell Therapeutics, Inc. Registration Statement on Form S-3, Submitted September 17, 2024 CIK No. 0001137 |
|
| September 24, 2024 |
As filed with the Securities and Exchange Commission on September 24, 2024 As filed with the Securities and Exchange Commission on September 24, 2024 Registration No. |
|
| September 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Brainstorm Cell Therapeutics Inc. |
|
| September 17, 2024 |
As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No. |
|
| September 16, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BRAINSTORM CELL THERAPEUTICS INC. a Delaware corporation Brainstorm Cell Therapeutics Inc. (hereinafter called the “Corporation”), organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: The Board of Directors of the Corporation, by unanimous writt |
|
| September 16, 2024 |
Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan Exhibit 10.5 BRAINSTORM CELL THERAPEUTICS INC. AMENDMENT NO. 4 TO 2014 STOCK INCENTIVE PLAN The 2014 Stock Incentive Plan (the “Plan”) of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), is hereby amended by this AMENDMENT NO. 4 as follows: Section 4(a)(1) of the Plan is hereby deleted in its entirety and a new Section 4(a)(1) is inserted in lieu thereof which shall read |
|
| September 16, 2024 |
Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan Exhibit 10.10 BRAINSTORM CELL THERAPEUTICS INC. AMENDMENT NO. 4 TO 2014 GLOBAL SHARE OPTION PLAN The 2014 Global Share Option Plan (the “Plan”) of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), is hereby amended by this AMENDMENT NO. 4 as follows: Section 5.1 of the Plan is hereby deleted in its entirety and anew Section 5.1 is inserted in lieu thereof which shall read |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation |
|
| September 4, 2024 |
Brainstorm Cell Therapeutics Inc. 1325 Avenue of the Americas, 28th Floor New York, NY 10019 Brainstorm Cell Therapeutics Inc. 1325 Avenue of the Americas, 28th Floor New York, NY 10019 September 4, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Brainstorm Cell Therapeutics Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-281827) Ladies and Gentlemen: P |
|
| August 28, 2024 |
Form of Subordinated Indenture (including Form of Subordinated Note) Exhibit 4.3 BRAINSTORM CELL THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Tr |
|
| August 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Brainstorm Cell Therapeutics, Inc. |
|
| August 28, 2024 |
Form of Senior Indenture (including Form of Senior Note) Exhibit 4.2 BRAINSTORM CELL THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Tru |
|
| August 28, 2024 |
As filed with the Securities and Exchange Commission on August 28, 2024 As filed with the Securities and Exchange Commission on August 28, 2024 Registration No. |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| August 14, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS SPA in place for Phase 3b NurOwn® trial in ALS Enhanced leadership team with appointment of Hartoun Hartounian Ph.D. a |
|
| August 14, 2024 |
EXHIBIT 10.8 BRAINSTORM CELL THERAPEUTICS INC. Restricted Stock Agreement Granted Under 2014 Stock Incentive Plan Name of Recipient: Stacy Lindborg Number of shares of restricted common stock awarded: 241,935 Grant Date: March 11, 2024 Brainstorm Cell Therapeutics Inc. (the “Company”) has selected you to receive the restricted stock award described above, which is subject to the provisions of the |
|
| August 14, 2024 |
EXHIBIT 10.2 April 16, 2024 PERSONAL AND CONFIDENTIAL Stacy Lindborg Re:Separation Agreement Dear Stacy: This letter confirms your separation from employment with Brainstorm Cell Therapeutics (the “Company”) effective as of May 9, 2024 (the “Separation Date”). This letter also proposes an agreement between you and the Company (the “Agreement”). First, a few formalities. Regardless of whether you s |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| August 14, 2024 |
EXHIBIT 10.1 June 19, 2024 Dr. Hartoun Hartounian Re: Employment Offer Dear Dr. Hartounian I am pleased to offer you employment with BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”). The initial terms of your employment, should you accept this offer, are set forth below (the “Agreement”). 1.Position. Your position will be Executive Vice President and Chief Operating Office |
|
| August 14, 2024 |
EXHIBIT 10.10 BRAINSTORM CELL THERAPEUTICS INC. 2014 GLOBAL SHARE OPTION PLAN AWARD AGREEMENT FOR RESTRICTED STOCK UNITS GRANTED UNDER SECTION 102(b)(2) OF THE ISRAELI INCOME TAX ORDINANCE TO EMPLOYEES, OFFICERS OR DIRECTORS AS 102 CAPITAL GAINS TRACK GRANT Unless otherwise defined herein, capitalized terms used in this Award Agreement shall have the same meanings as ascribed to them in the Brains |
|
| August 14, 2024 |
EXHIBIT 10.9 BRAINSTORM CELL THERAPEUTICS INC. 2014 GLOBAL SHARE OPTION PLAN AWARD AGREEMENT FOR RESTRICTED STOCK UNITS GRANTED UNDER SECTION 102(b)(2) OF THE ISRAELI INCOME TAX ORDINANCE TO EMPLOYEES, OFFICERS OR DIRECTORS AS 102 CAPITAL GAINS TRACK GRANT Unless otherwise defined herein, capitalized terms used in this Award Agreement shall have the same meanings as ascribed to them in the Brainst |
|
| August 14, 2024 |
EXHIBIT 10.7 BRAINSTORM CELL THERAPEUTICS INC. 2014 GLOBAL SHARE OPTION PLAN AWARD AGREEMENT FOR RESTRICTED STOCK UNITS GRANTED UNDER SECTION 102(b)(2) OF THE ISRAELI INCOME TAX ORDINANCE TO EMPLOYEES, OFFICERS OR DIRECTORS AS 102 CAPITAL GAINS TRACK GRANT Unless otherwise defined herein, capitalized terms used in this Award Agreement shall have the same meanings as ascribed to them in the Brainst |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| August 14, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 28, 2024 |
Exhibit 10.3 [], 2024 Holder of Warrants to Purchase Common Stock issued on July 19, 2023 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-3 (File No. 333-258640) on or about the date hereof (the “Offering”) by Brainstorm Cell Therapeutics Inc. (the “Company”) of shares of common stock, par value $0.00005 per share (the “Common Stock”), and/or othe |
|
| June 28, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258640 Prospectus Supplement (To Prospectus Dated August 19, 2021) 7,918,764 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,192,347 Shares of Common Stock 3,192,347 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering an aggregate of 7,918,764 shares of our common stock, $0.00005 par value per share (the “Co |
|
| June 28, 2024 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT [], 2024 Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Attention: Chaim Lebovits, President and Chief Executive Officer Dear Mr. Lebovits: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Brainstorm Cell Therapeutics Inc., a Delaware corporation (the |
|
| June 28, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 28, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT brainstorm cell therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations o |
|
| June 28, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 28, 2024 |
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering Exhibit 99.1 BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering NEW YORK, June 27, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investo |
|
| June 28, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [ ], 2024 between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and |
|
| June 27, 2024 |
Up to $8,000,000 Common Stock Brainstorm Cell Therapeutics Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-258640 PROSPECTUS SUPPLEMENT (To Prospectus dated August 19, 2021) Up to $8,000,000 Common Stock Brainstorm Cell Therapeutics Inc. This prospectus supplement amends and supplements the information in the prospectus, dated August 19, 2021, filed as a part of our registration statement on Form S-3 (File No. 333-258640), or the Base Prospectus, as |
|
| June 26, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial NEW YORK, June 26, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, |
|
| June 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 20, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appo |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| May 3, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Comm |
|
| April 17, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK, April 16, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeuti |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| April 11, 2024 |
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule Exhibit 99.1 BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule NEW YORK, April 11, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, “the Company”), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the “Notification Letter on Compliance”) on April 10, 2024 from th |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| April 9, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, April 9, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it receive |
|
| April 2, 2024 |
Exhibit 1.1 Brainstorm Cell Therapeutics Inc. AMENDMENT NO. 1 TO The DISTRIBUTION AGREEMENT April 2, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Ladies and Gentlemen: Brainstorm Cell Therapeutics Inc. (the “Company”), together with Leerink Partners LLC (“Leerink Partn |
|
| April 2, 2024 |
Up to $14,389,024 of Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258640 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated August 19, 2021 and Prospectus dated August 19, 2021) Up to $14,389,024 of Shares Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in our prospectus supplement dated August 19, 2021 (the “ATM Prospectus Supplement”). This Prospec |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| April 1, 2024 |
Exhibit 10.69 Personal Employment Agreement This employment agreement is made and signed in Petah Tikva on the 23rd day of December, 2012. Between: Brainstorm Therapeutics Ltd., Company Registration No. 513601021, located at 12 Basel Street, Petah Tikva 49001 (hereinafter: “the Company”); And: Alla Patlis, ID No. [***], residing at [***], Phone No. [***] (hereinafter: “the Employee”). Whereas the |
|
| April 1, 2024 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK, April 1, 2024 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial resul |
|
| April 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| April 1, 2024 |
Brainstorm Cell Therapeutics Inc. Compensation Recovery Policy Exhibit 97.1 BRAINSTORM CELL THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Adopted as of November 13, 2023 Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation f |
|
| April 1, 2024 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. |
|
| April 1, 2024 |
Exhibit 10.72 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is entered into as of the date set forth below, effective as of May 1st, 2020 (the “Effective Date”), by and between Brainstorm Cell Therapeutics Ltd., a company organized under the laws of the State of Israel, with offices at 12 Bazel street Petah-Tikvah, Israel, registered # 513601021, (the “Company”) and Alla Patli |
|
| April 1, 2024 |
Exhibit 10.70 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is entered into as of the date set forth below, effective as of March 1st, 2015 (the “Effective Date”), by and between Brainstorm Cell Therapeutics Ltd., a company organized under the laws of the State of Israel, with offices at 12 Bazel street Petah-Tikvah, Israel, registered # 513601021, (the “Company”) and Alla Pat |
|
| April 1, 2024 |
Exhibit 10.71 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is entered into as of the date set forth below, effective as of April 1st, 2019 (the “Effective Date”), by and between Brainstorm Cell Therapeutics Ltd., a company organized under the laws of the State of Israel, with offices at 12 Bazel street Petah-Tikvah, Israel, registered # 513601021, (the “Company”) and Alla Pat |
|
| April 1, 2024 |
Exhibit 10.73 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is entered into as of the date set forth below, effective as of August 1st, 2022 (the “Effective Date”), by and between Brainstorm Cell Therapeutics Ltd., a company organized under the laws of the State of Israel, with offices at 12 Bazel street Petah-Tikvah, Israel, registered # 513601021, (the “Company”) and Alla Pa |
|
| April 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPE |
|
| February 12, 2024 |
BCLI / Brainstorm Cell Therapeutics Inc. / Ness Kevin Dean - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value (Title of Class of Securities) 10501E 201 (CUSIP Number) Febuary 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| December 20, 2023 |
BrainStorm Issues 2023 Letter to Shareholders Exhibit 99.1 BrainStorm Issues 2023 Letter to Shareholders NEW YORK, Dec. 20, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Shareholders, We remain steadfast in our commitment to advancing NurOwn as a promising treatment for ALS patients. Recognizi |
|
| November 22, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS Meeting will take place on December 6; Company plans to seek Special Protocol Assessment (SPA) NEW YORK, Nov. 20, 2023 /PRNewswire/ -BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dis |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant: x Filed by a Party other than the Registrant: ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only ( |
|
| November 22, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 14, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, November 14, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the th |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| October 24, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn® for the Treatment of ALS - Resource consumption will be reduced by 50% to accelerate ALS development - Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, October 24, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult |
|
| August 14, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update FDA advisory committee (ADCOM) meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis (ALS) scheduled for September 27, 2023 BrainStorm's Biologics License Application (BLA) for NurOwn has a Prescription Drug User Fee Act (PDUFA) action date targeted to occur by December 8, |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| July 19, 2023 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 17, 2023 Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Attention: Chaim Lebovits, President and Chief Executive Officer Dear Mr. Lebovits: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Brainstorm Cell Therapeutics Inc., a Delaware corporation |
|
| July 19, 2023 |
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering Exhibit 99.1 Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering NEW YORK, July 17, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the “Company”), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investo |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| July 19, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| July 19, 2023 |
4,054,055 Shares of Common Stock Warrants to Purchase up to 4,054,055 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258640 Prospectus Supplement (To Prospectus Dated August 19, 2021) 4,054,055 Shares of Common Stock Warrants to Purchase up to 4,054,055 Shares of Common Stock We are offering an aggregate of 4,054,055 shares of our common stock, $0.00005 par value per share (the “Common Stock”) and warrants to purchase up to 4,054,055 shares of our Common Stoc |
|
| July 19, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT brainstorm cell therapeutics inc. Warrant Shares: Initial Exercise Date: , 2023 Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on e |
|
| June 20, 2023 |
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair Exhibit 99.1 BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair NEW YORK, June 20, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| June 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| June 6, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 PDUFA target action date set to occur by December 8, 2023 NEW YORK, June 6, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| May 15, 2023 |
EX-99.1 2 tm2315779d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, May 15, 2023 /PRNewswire/ - BrainStorm |
|
| April 5, 2023 |
BCLI / Brainstorm Cell Therapeutics, Inc. / Ness Kevin Dean - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value (Title of Class of Securities) 10501E 201 (CUSIP Number) March 17, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 30, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update Biologics License Application for NurOwn® for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, March 30, 2023 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading develop |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 30, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPE |
|
| March 30, 2023 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. |
|
| March 30, 2023 |
Description of the Company’s Securities. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Brainstorm Cell Therapeutics Inc., a Delaware corporation, is a summary of certain provisions of our securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and does not purport to be complete. It is subject to and qualified in its entirety |
|
| March 27, 2023 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS Conference call and webcast at 8:00 a.m. ET NEW YORK, March 27, 2023 /PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that t |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| January 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| January 4, 2023 |
Exhibit 10.1 CONFIDENTIAL AMENDMENT No. 3 TO OFFER LETTER AGREEMENT This AMENDMENT NO. 3 TO OFFER LETTER AGREEMENT (the “Amendment”) is effective as of the date on which the last party executes this Amendment (“Amendment Effective Date”), by and between BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation with a mailing address of 1325 Avenue of Americas, 28th Floor New York, NY 10019 (the “C |
|
| January 4, 2023 |
Exhibit 10.2 SEPARATION AGREEMENT This SEPARATION AGREEMENT (this “Agreement”) is effective as of the date on which the last Party executes this Agreement (the “Effective Date”), by and between Ralph Kern, an individual with a mailing address of 959 First Avenue, New York, NY 10022 (“Executive”), and Brainstorm Cell Therapeutics Inc., a company registered under the laws of the State of Delaware wi |
|
| January 4, 2023 |
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer Exhibit 99.1 BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer NEW YORK, January 4, 2023 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer. This promotion launches a tar |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 14, 2022 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm to request Type A meeting with FDA to facilitate NurOwn’s advancement following receipt of a refusal to file letter regarding the company’s new Biologics License Application Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, November 14, 2022 - Brai |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| October 12, 2022 |
Exhibit 99.1 BrainStorm Presents New Biomarker Analyses from NurOwn’s Phase 3 ALS Trial at the ALS ONE Research Symposium NurOwn® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced ALS and less advanced disease, confirming the importance of accounting for ALSFRS-R floor effects |
|
| October 12, 2022 |
Exhibit 99.2 The Relationship between CSF Biomarkers and Efficacy of Treatment with NurOwn (MSC - NTF cells) ALS ONE, Industry Presentations Stacy R. Lindborg, Ph.D. Chief Development Officer, Brainstorm Cell Therapeutics October 7, 2022 2 Number of participants with baseline ALSFRS - R 25 = 44 of 189 (23.3%) Participants with baseline ALSFRS - R 25 are impacted by the floor of the scale NurOwn Ph |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation |
|
| September 22, 2022 |
Exhibit 10.1 AMENDMENT No. 2 TO OFFER LETTER AGREEMENT This AMENDMENT NO. 2 TO OFFER LETTER AGREEMENT (the ?Amendment?) is effective as of September 18, 2022 (?Amendment Effective Date?), by and between BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation with a mailing address of 1325 Avenue of Americas, 28th Floor New York, NY 10019(the ?Company?), and DR. STACY LINDBORG, an individual, wit |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| August 15, 2022 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn? for the treatment of ALS New clinical analyses reinforce the conclusions from NurOwn?s? Phase 3 clinical trial Conference call and webcast at 8:00 a.m. Eastern |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 16, 2022 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn? Strengthened executive team in preparation for anticipated growth and corporate development, with the appointment of Ne |
|
| March 28, 2022 |
Exhibit 10.54 Brainstorm Cell Therapeutics Inc. 4th Amendment to the Second Amended and Restated Director Compensation Plan (adopted October 28, 2021) This 4th Amendment to the Second Amended and Restated Director Compensation Plan is hereby adopted by the Board of Directors (the ?Board?) of Brainstorm Cell Therapeutics Inc. (the ?Corporation?) and amends the Second Amended and Restated Director C |
|
| March 28, 2022 |
Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update BrainStorm continues to collect and leverage expert feedback as it pursues the optimal path forward to provide broad access to NurOwn? for patients with ALS Announced the peer reviewed publication of the full analysis of the NurOwn Phase 3 trial in ALS showing greater treatment effe |
|
| March 28, 2022 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. ? Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland ? * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 28, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 14, 2022 |
BCLI / Brainstorm Cell Therapeutics Inc / Abbhi Investments, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value per share (Title of Class of Securities) 10501E201 (CUSIP Number) Jared Kelly, Esq. Lowenstein Sandler LLP 1251 Avenue of the Americas New York 10020 (212) 262-6700 (Name, |
|
| February 14, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| January 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| January 28, 2022 |
EX-99.1 2 tm223729d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update BrainStorm remains committed to pursuing the best and most expeditious path forward to facilitate access to NurOwn® for people living with ALS Presented important new ALS biomarker data at NEALS meeting showing significant NurOwn-drive |
|
| January 28, 2022 |
Transcript of BrainStorm Cell Therapeutics, Inc. Third Quarter 2021 Earnings Call November 15, 2021 Exhibit 99.2 Transcript of BrainStorm Cell Therapeutics, Inc. Third Quarter 2021 Earnings Call November 15, 2021 Participants Michael Wood - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer, BrainStorm Cell Therapeutics, Inc. Alla Patlis - Interim Chief Financial Officer, BrainStorm Cell Therapeutics, Inc. Stacy Lindborg - Executive Vice President & Chief Development O |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| December 10, 2021 |
As filed with the Securities and Exchange Commission on December 10, 2021 As filed with the Securities and Exchange Commission on December 10, 2021 Registration No. |
|
| November 15, 2021 |
Exhibit 10.1 ? Brainstorm Cell Therapeutics Inc. ? 4th Amendment to the Second Amended and Restated Director Compensation Plan ? (adopted October 28, 2021) ? This 4th Amendment to the Second Amended and Restated Director Compensation Plan is hereby adopted by the Board of Directors (the ?Board?) of Brainstorm Cell Therapeutics Inc. (the ?Corporation?) and amends the Second Amended and Restated Dir |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: x Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Sta |
|
| October 29, 2021 |
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors Exhibit 99.1 Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors NEW YORK, Oct. 28, 2021 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors. The appointment becomes effective on October 28, 20 |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) ( |
|
| August 17, 2021 |
Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 August 17, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Brainstorm Cell Therapeutics Inc.: Registration Statement on Form S-3 filed August 9, 2021 (File No. 333- 258640) Ladies and Gentlemen: Pursuant |
|
| August 13, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| August 9, 2021 |
Form of Senior Indenture (including Form of Senior Note) Exhibit 4.2 BRAINSTORM CELL THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Tru |
|
| August 9, 2021 |
As filed with the Securities and Exchange Commission on August 9, 2021 As filed with the Securities and Exchange Commission on August 9, 2021 Registration No. |
|
| August 9, 2021 |
Exhibit 1.2 DISTRIBUTION AGREEMENT August 9, 2021 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Ladies and Gentlemen: Brainstorm Cell Therapeutics Inc., a Delaware corporation (the ?Company?), confirms its agreement with SVB Leerink LLC (?SVB Leerink?) and Raymond James & Associa |
|
| August 9, 2021 |
Form of Subordinated Indenture (including Form of Subordinated Note) Exhibit 4.3 BRAINSTORM CELL THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Tr |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| August 5, 2021 |
Exhibit 99.1 BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update Continuing to assess regulatory strategy for advancing NurOwn? towards potential approval in ALS Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, August 5, 2021 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerativ |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Com |
|
| April 26, 2021 |
Exhibit 99.1 BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update Positive Phase 2 data demonstrate the potential of NurOwn? as a treatment for progressive MS Regulatory strategy progressing to advance NurOwn?s approval in ALS Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, April 26, 2021 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), |
|
| April 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| April 26, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPE |
|
| February 4, 2021 |
EXHIBIT 10.63 May 26, 2020 Stacy Lindborg Re: Offer of Employment Dear Dr. Lindborg: I am pleased to confirm an offer for you, by way of this offer letter (this “Letter”), to join BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”), on a full-time basis, in the position of Executive Vice President, Head of Global Clinical Research. Your employment commencement date shall be J |
|
| February 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| February 4, 2021 |
Exhibit 99.1 BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update Company met with the FDA to present phase 3 data and is in ongoing discussions with the FDA to identify agreed upon regulatory pathways that may support NurOwn’s future approval in ALS Progressive MS Phase 2 trial remains on track for top-line data readout in Q1 2021 Conference call and webcast at 8 |
|
| February 4, 2021 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. |
|
| November 17, 2020 |
Exhibit 99.1 BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study Clinical trial did not meet statistical significance in primary efficacy endpoint NurOwn® showed a clinically meaningful treatment response compared to placebo in a pre-specified subgroup CSF biomarker analyses confirmed NurOwn® resulted in a statistically significant increase of neurotrophic factors and reduction in |
|
| November 17, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| November 12, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 (November 10, 2020) Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdicti |
|
| October 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 (October 22, 2020) Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction |
|
| October 27, 2020 |
Exhibit 99.1 Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® SOMERSET, N.J. and New York – October 22, 2020 — Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, a |
|
| October 27, 2020 |
Exhibit 99.2 Media Contact: Zachary DeRitis Communications Specialist 215-409-4249 [email protected] Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm’s U.S. Manufacturing Facility RR&D to lead site selection and design Site analyses to begin immediately Philadelphia, PA. and New York - October 26, 2020 - Rapid Reshore & De |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36641 BRAINSTOR |
|
| October 15, 2020 |
Exhibit 99.1 BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update Pivotal Phase 3 ALS trial remains on track for top-line data readout by the end of November 2020 New senior executives strengthen regulatory and market access capabilities as the Company prepares to transition to a commercial organization Conference Call and Webcast at 8 a.m. ET Today |
|
| October 15, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| October 1, 2020 |
Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: x Filed by a Party other than the Registrant: ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Sta |
|
| September 25, 2020 |
Exhibit 1.1 AMENDED AND RESTATED DISTRIBUTION AGREEMENT September 25, 2020 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Ladies and Gentlemen: Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and Raymond James & Associates, Inc. (“Raymond James”) are par |
|
| September 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation |
|
| September 25, 2020 |
BRAINSTORM CELL THERAPEUTICS INC. Up to $45,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-225517 PROSPECTUS SUPPLEMENT (To Prospectus dated June 29, 2018) BRAINSTORM CELL THERAPEUTICS INC. Up to $45,000,000 Common Stock This prospectus supplement and the accompanying prospectus relate to the offer and sale from time to time of shares of our common stock, par value $0.00005 per share, having an aggregate offering price of up to $45,0 |
|
| September 3, 2020 |
Offer Letter by and between Brainstorm Cell Therapeutics Inc. and Anthony Waclawski. Exhibit 10.1 September 2, 2020 Anthony Waclawski Re: Offer of Employment Dear Anthony: I am pleased to confirm an offer for you, by way of this offer letter (this “Letter”), to join BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”) on a full-time basis, in the position of Executive Vice President (EVP), Global Head of Regulatory Affairs. Your employment commencement date sh |
|
| September 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) |
|
| August 10, 2020 |
BRAINSTORM CELL THERAPEUTICS INC. 2,458,201 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-225995 Prospectus Supplement No. 3 (to Prospectus dated September 28, 2018, Prospectus Supplement No. 1 dated August 2, 2019 and Prospectus Supplement No. 2 dated June 25, 2020) BRAINSTORM CELL THERAPEUTICS INC. 2,458,201 Shares of Common Stock This prospectus supplement, together with the prospectus listed above, is to be used by cer |
|
| August 5, 2020 |
Third Amendment to Employment Agreement dated June 23, 2020 between the Company and Chaim Lebovits. Exhibit 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this "Amendment"), effective June 23, 2020, amends the Employment Agreement (as amended from time to time, the "Agreement") by and among Brainstorm Cell Therapeutics Ltd., Brainstorm Cell Therapeutics Inc., and Chaim Lebovits. NOW, THEREFORE, in consideration of the mutual promises contained herein a |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36641 BRAINSTORM CEL |
|
| August 5, 2020 |
Amendment to Employment Agreement dated June 23, 2020 between the Company and Uri Yablonka. Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this "Amendment"), effective June 23, 2020, amends the Employment Agreement (as amended from time to time, the "Agreement") by and between Brainstorm Cell Therapeutics Ltd. and Uri Yablonka. NOW, THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, the re |
|
| June 26, 2020 |
BRAINSTORM CELL THERAPEUTICS INC. 2,458,201 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-225995 Prospectus Supplement No. 2 (to Prospectus dated September 28, 2018 and Prospectus Supplement No. 1 dated August 2, 2019) BRAINSTORM CELL THERAPEUTICS INC. 2,458,201 Shares of Common Stock This prospectus supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities o |
|
| June 26, 2020 |
8-K 1 tm2023455d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other j |
|
| June 26, 2020 |
BRAINSTORM CELL THERAPEUTICS INC. 842,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-233349 Prospectus Supplement No. 1 (to Prospectus dated August 30, 2019) BRAINSTORM CELL THERAPEUTICS INC. 842,000 Shares of Common Stock This prospectus supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities or by their pledgees, donees, transferees or other successo |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36641 BRAINSTORM CE |
|
| April 8, 2020 |
EXHIBIT 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| April 8, 2020 |
BCLI / BrainStorm Cell Therapeutics Inc. / Abbhi Investments, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value per share (Title of Class of Securities) 10501E201 (CUSIP Number) Christopher Sheaffer, Esq. Jared Kelly, Esq. Reed Smith LLP 599 Lexington Avenue New York, NY 10022-7650 |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| April 3, 2020 |
Exhibit 10.1 April 1, 2020 David Setboun Re: Offer of Employment Dear Mr. Setboun: I am pleased to confirm an offer for you, by way of this offer letter (this “Letter”), to join BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”), on a full-time basis, in the position of Executive Vice President, Chief Operating Officer (“COO”). Your employment commencement date shall be Apri |
|
| March 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (C |
|
| March 18, 2020 |
BCLI / BrainStorm Cell Therapeutics Inc. / Abbhi Investments, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value per share (Title of Class of Securities) 10501E201 (CUSIP Number) Christopher Sheaffer, Esq. Jared Kelly, Esq. Reed Smith LLP 599 Lexington Avenue New York, NY 10022-7650 |
|
| March 18, 2020 |
EXHIBIT 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| March 6, 2020 |
Exhibit 4.1 EXECUTION VERSION COMMON STOCK PURCHASE WARRANT Brainstorm Cell Therapeutics, Inc. Warrant Shares: 250,000 Issue Date: March 6, 2020 Initial Exercise Date: March 6, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Abbhi Investments, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the |
|
| March 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| March 6, 2020 |
EX-1.1 2 tm2011854d1ex1-1.htm EXHIBIT 1.1 EXHIBIT 1.1 DISTRIBUTION AGREEMENT March 6, 2020 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Attention: Stuart Barich Ladies and Gentlemen: Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement with Raymond James & Associates, Inc., as agent and/or principal under any Term |
|
| March 6, 2020 |
BRAINSTORM CELL THERAPEUTICS INC. Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-225517 PROSPECTUS SUPPLEMENT (To Prospectus dated June 29, 2018) BRAINSTORM CELL THERAPEUTICS INC. Up to $50,000,000 Common Stock This prospectus supplement and the accompanying prospectus relate to the offer and sale from time to time of shares of our common stock, par value $0.00005 per share, having an aggregate offering price of up to $50,0 |
|
| March 6, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-225517 PROSPECTUS SUPPLEMENT (To Prospectus dated June 29, 2018) BRAINSTORM CELL THERAPEUTICS INC. 1,250,000 shares of Common Stock and a Warrant for the purchase of up to 250,000 shares of Common Stock This prospectus supplement and the accompanying prospectus relate to the offer and sale of 1,250,000 shares of our Common Stock, par value $0.0 |
|
| March 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 Brainstorm Cell Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-36641 20-7273918 (State or other jurisdiction of incorporation) (Co |
|
| March 6, 2020 |
Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 6, 2020, between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and Abbhi Investments, LLC, a Delaware limited liability company (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to |
|
| March 6, 2020 |
Brainstorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share Exhibit 99.1 Brainstorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share NEW YORK, March. 6, 2020 - BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Fl |
|
| February 18, 2020 |
EXHIBIT 21 Subsidiaries of Brainstorm Cell Therapeutics Inc. Subsidiary Jurisdiction of Incorporation BrainStorm Cell Therapeutics Ltd. Israel Advanced Cell Therapies Ltd.* Israel BrainStorm Cell Therapeutics UK Ltd.* United Kingdom Brainstorm Cell Therapeutics Limited* Ireland * Wholly owned subsidiary of BrainStorm Cell Therapeutics Ltd. 1 |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact |
